anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Understanding these genetic alterations and the factors which contribute to this process would be critical for the identification of novel immunotherapeutic targets which may synergize with the T cell-targeted checkpoint inhibitors. Furthermore, this work promises to provide greater insight into tumor-mediated immune evasion mechanisms and primary immunotherapy resistance, potentially unveiling predictive markers of clinical response for our expanding arsenal of immune checkpoint inhibitor therapies.

Many patients who exhibit a response to the anti-PD-1 antibodies develop a prolonged course of disease stability which resembles the equilibrium phase of the previously proposed process of cancer immunoediting. This state of equipoise has been hypothesized to involve genetic alterations that promote immune evasion and, in some cases, lead to the development of tumor escape. Based on our data, the investigators propose that melanomas that develop a period of disease stability in response to anti-PD-1 immunotherapy exhibit genetic alterations that suppress the effectiveness of anti-tumor immunity. Our previous studies indicate that the tumor-derived factors that play a role in the paracrine signaling pathways capable of regulating nearby stromal cell populations are more likely to be critical immune regulators of the tumor microenvironment. Therefore, the investigators will focus our studies on those differentially expressed genes which encode soluble proteins using an available prediction algorithm. Those genes identified by this study to be differentially expressed in the melanoma tissues of patients demonstrating a clinical response to immune checkpoint inhibitor therapy will be further evaluated in transgenic autochthonous melanoma models.
The initial clinical trials of carvedilol phosphate extended-release capsules in subjects with hypertension, heart failure, and left ventricular dysfunction following myocardial infarction did not include sufficient numbers of subjects aged 65 years or older to determine whether they respond differently from younger patients.

A randomized trial (n = 405) comparing subjects with mild to severe heart failure switched to carvedilol phosphate extended-release capsules or maintained on immediate-release carvedilol tablets included 220 subjects who were aged 65 years or older. In this elderly subgroup, the combined incidence of dizziness, hypotension, or syncope was 24% (18/75) in subjects switched from the highest dose of immediate-release carvedilol tablets (25 mg twice daily) to the highest dose of carvedilol phosphate extended-release capsules (80 mg once daily) compared with 11% (4/36) in subjects maintained on immediate-release carvedilol tablets (25 mg twice daily). When switching from the higher doses of immediate-release carvedilol tablets to carvedilol phosphate extended-release capsules, a lower starting dose is recommended for elderly patients [see Dosage and Administration (2.5)].

The following information is available for trials with immediate-release carvedilol. Of the 765 subjects with heart failure randomized to carvedilol in U.S. clinical trials, 31% (235) were aged 65 years or older, and 7.3% (56) were aged 75 years or older. Of the 1,156 subjects randomized to carvedilol in a long-term, placebo-controlled trial in severe heart failure, 47% (547) were aged 65 years or older, and 15% (174) were aged 75 years or older. Of 3,025 subjects receiving carvedilol in heart failure trials worldwide, 42% were aged 65 years or older. Of the 975 subjects with myocardial infarction randomized to carvedilol in the CAPRICORN trial, 48% (468) were aged 65 years or older, and 11% (111) were aged 75 years or older. Of the 2,065 hypertensive subjects in U.S. clinical trials of efficacy or safety who were treated with carvedilol, 21% (436) were aged 65 years of age or older. Of 3,722 subjects receiving immediate-release carvedilol in hypertension clinical trials conducted worldwide, 24% were aged 65 years or older.

With the exception of dizziness in hypertensive subjects (incidence 8.8% in the elderly versus 6% in younger subjects), no overall differences in the safety or effectiveness (see Figures 2 and 4) were observed between the older subjects and younger subjects in each of these populations. Similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
Diagnosing HIV soon after infection can benefit individuals and also has important public health benefits. It has been shown that starting antiretroviral therapy (ART) before HIV has progressed results in a better response to treatment and gives the person a better chance of long-term survival with HIV. Treating HIV can also reduce the risk that someone will transmit HIV to his or her sexual partners. The first step in achieving these individual and population level benefits is testing people for HIV. Unfortunately, in many parts of the world, including Kenya where we plan to conduct this study, many people are not tested regularly and do not know that they are infected. This study involves providing a public health service, notification of an exposure to a communicable disease and HIV testing, to sexual partners of those who test HIV-positive at voluntary counseling and testing (VCT) clinics in Kenya. Sexual partners are identified voluntarily by the person who tests at the VCT. A public health provider then goes to the home of the sexual partners to offer them HIV counseling and testing. This process is called provision of assisted partner services (aPS).

We propose a cluster randomized clinical trial which will be conducted in collaboration with the Kenya Ministry of Health (MOH) at 18 rural and urban voluntary counseling and testing (VCT) facilities across Kenya. Proposed activities will assess the effectiveness and cost-effectiveness of providing aPS, improve capacity for program implementation in Kenya, and lay the foundation for evaluating the program's impact at the national level.
[pre-glass agglomeration] A method of making a fragrance delivery system comprising forming fused microspheres and incorporating a fragrance therein. The method relates to the mixing together of two separate factions comprising a silicate part and a modifier part, drying the mixture, heating the mixture to form an agglomeration, removing any free-flowing spheres from the agglomeration, soaking the agglomeration in fragrances or essential oils, and then drying the agglomeration. [incorporated therein. The preglass agglomeration has an extended fragrance release time exceeding a year and a half, and uses microcapillary action to quickly uptake oils and alcohols. The pre-glass agglomeration provides a slow release of fragrance without the escape of any residual liquid. The pre-glass agglomeration may be replenished, an unlimited number of times, with fragrance containing oils and alcohols after the odor fades. The pre-glass agglomerations can be molded and may be colored or dyed.]
After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
This study randomly assigns smokers who do not have a quit date set to either a smoking reduction grop or usual care group. The smoking reduction group receives behavioral counseling on smoking reduction and nicotine patch and/or gum to reduce the number of cigarettes smoked per day by at least 50%. The usual care group is given brief advice to quit smoking and referral to local cessation services. To be included in the study, participants must have peripheral arterial disease (defined as ankle Brachial Index equal to or less than 0.85 or history of prior revascularization) and they must be daily smokers (defined as at least 1 cigarette, cigar, or tobacco pipe daily). Participants complete questionnaires that measure mood, functional ability, smoking history, and motivation to quit smoking. Participants will be followed in this study for up to 24 months.
Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of the metabolites being recovered in the urine. In a small study comparing a single dose of lamotrigine in patients with varying degrees of renal impairment with healthy volunteers, the plasma half-life of lamotrigine was significantly longer in the patients with renal impairment [see ]. Clinical Pharmacology (12.3)

Initial doses of lamotrigine should be based on patients' AED regimens; reduced maintenance doses may be effective for patients with significant renal impairment. Few patients with severe renal impairment have been evaluated during chronic treatment with lamotrigine. Because there is inadequate experience in this population, lamotrigine should be used with caution in these patients [see ]. Dosage and Administration (2.1)
Sepsis is a major contributor to poor child health outcomes around the world. The high morbidity, mortality, and societal cost associated with paediatric sepsis render it a global health priority, as summarised in Paper 1 of this Series. Sepsis is characterised by a dysregulated host response to infection that manifests as organ failure, and children are uniquely susceptible to sepsis, as discussed in Paper 2. The focus of this third Series paper is quality improvement in paediatric sepsis. The 2017 WHO resolution on sepsis outlined key aims to reduce the burden of sepsis. As of 2024, only a small number of countries have implemented systematic, paediatric-focused quality improvement programmes to raise sepsis awareness, enhance recognition of sepsis, promote timely treatment, and provide long-term support for paediatric sepsis survivors. We examine programme successes and systematic barriers to quality improvement targeting paediatric sepsis. We highlight the need for programme design to consider the entire patient journey, starting with prevention, caregiver awareness, recognition at home, education of the health-care workforce, development of health-care systems, and establishment of long-term family and survivor support extending beyond the intensive care unit. Building on lessons learnt from existing quality improvement programmes, we outline implementation strategies and measures to enable benchmarking. Ultimately, quality improvement on a global scale can only be accelerated through a global learning platform focusing on paediatric sepsis.
A total of 150 subjects in this group received apalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
PURPOSE:To prepare a gamma-globulin derivative composed mainly of the monomer, having low anticomplimentary action, and administrable by intravenous injection, easily, in an industrial scale, by treating a sulfonated gamma-globulin in a buffer solution for development with an ion exchanger, thereby removing coagulated globulin molecules. CONSTITUTION:A solfonated gamma-globulin is treated either with an anion exchanger (e.g. DEAE-Sepharose) in a buffer solution for developing use having a pH of 4-10 and an ionic strength of 0.01-0.15, or with a cationic exchanger in a buffer solution having a pH of 4-6.5 and an ionic strength of 0.01-0.1. Most of the monomolecular sulfonated gamma-globulin molecules are adsorbed to the ion exchanger by the treatment, and the coagulated sulfonated gamma-globulin and the non-sulfonated gamma-globulin molecules are passed through the ion exchanger unabsorbed. The absorbed monomolecular sulfonated gamma-globulin molecules are eluted with a buffer solution having a pH of 3-8 (anionic exchanger) or of 6-9 (cationic exchanger). The recovered sulfonated gamma-globulin is purified by conventional process.
A stand-alone web-based rapid anatomical documentation (RAD) system searches for ICD codes linked to key words that are applied to a standards-based structured vocabulary. The RAD system provides a search screen divided into a plurality of display regions for selecting a search type from the search screen. The search type includes a text search and anatomy search. Based on the type of search initialed, search filters and ICD codes are made available. Selecting at least one search filter causes an update of the search filters and ICD codes available, wherein the selection of the search filters can be repeated until a number of codes available reach a minimum value. Each ICD code is linked to keywords hierarchically organized and associated with the search filters, links to defined regions on anatomical art images and clinically relevant information.
Water-insoluble, acid-soluble, film-forming modified polymers are prepared by esterifying polyvinyl alcohol with monochloracetic acid, etherifying the esterified product obtained with dihydropyrane and aminating the esterified and etherified product with a dialkylamine containing 1 to 4 carbon atoms in each alkyl radical. The esterification and etherification may be effected in the presence of a mineral acid, e.g. hydrochloric or sulphuric acid, and the amination in the presence of an organic solvent, e.g. methanol. Specified amines are diethylamine, dipropylamine and dibutylamine. In an example, polyvinyl alcohol is reacted with monochloracetic acid, and dihydropyane in the presence of hydrochloric acid, and with dipropylamine in the presence of methanol.  The modified polymers may be dissolved in organic solvents, e.g. acetone, methanol, ethanol, chloroform or ethyl acetate, and the compositions so obtained used for coating pharmaceutical tablets.  Such coating compositions may also comprise colouring matter, e.g. b -carotene and titanium dioxide, polyethylene glycols, sweetening agents such as cyclohexylsulphamic acid, and edible oils such as rape seed and castor oils.
A system and method are provided for enabling a user to annotate a medical image. A collection of key-value pairs is provided, in which a key represents an image-observable quantity and a value represents the value of the image-observable quantity. A collection of structured finding objects is provided, wherein each structured finding object represents a set of key-value pairs, each set of key-value pairs representing a different annotation of the medical image. The user is enabled to select one or more of the collection of key-value pairs, thereby obtaining a user-selected structured finding object which represents a preliminary annotation of the medical image by the user. At least one recommended structured finding object is selected by using the user-selected structured finding object as input to a probabilistic recommendation algorithm. Feedback is provided to the user on the basis of the recommended structured finding object. The annotation is well suited for, e.g., pointer-based selection via a graphical user interface, speech recognition, etc. Moreover, machine interpretability may be improved compared to conventional string-based annotation.
A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents.
Pseudolaric acid B (PAB), an acid isolated from the roots of Pseudolarix kaempferi gorden, has shown antitumour effects through multiple mechanisms of action. The objective of this study was to investigate the anticancer effect of PAB on non-small cell lung cancer (NSCLC) and its underlying mechanism. In our experiments, we observed that PAB decreased cell viability, inhibited colony formation, induced cell cycle arrest, impeded scratch healing, and increased apoptosis in H1975 and H1650 cells. Additionally, PAB treatment enhanced the fluorescence intensity of MDC staining in NSCLC cells, upregulated the protein expression of microtubule-associated protein light chain 3 II (LC3 II), and downregulated the expression of sequestosome 1 (SQSTM1/P62). Combined treatment with PAB and chloroquine (CQ) increased the protein expression levels of LC3 II and P62 while decreasing the apoptosis of H1975 and H1650 cells. Moreover, treatment with PAB led to significant mTOR inhibition and AMPK activation. PAB combined with compound C (CC) inhibited autophagy and apoptosis. Furthermore, PAB treatment increased intracellular reactive oxygen species (ROS) levels in NSCLC cells, which correlated with the modulation of the AMPK/mTOR signalling pathway and was associated with autophagy and apoptosis. Finally, we validated the antitumour growth activity and mechanism of PAB in vivo using athymic nude mice bearing H1975 tumour cells. In conclusion, our findings suggest that PAB can induce apoptosis and autophagic cell death in NSCLC through the ROS-triggered AMPK/mTOR signalling pathway, making it a promising candidate for future NSCLC treatment.
1343526 Microcapsules FUJI PHOTO FILM CO Ltd 26 July 1971 [27 July 1970 31 July 1970] 35025/71 Heading B8C Microcapsules are prepared by a conventional coacervation process applied to a dispersion of a water-immiscible substance (solid or liquid) in an aqueous colloidal solution of at least one hardenable, hydrophilic, wall-forming polymer, which is or which comprises gelatine, a phenolic compound being added to the system at some time before the microcapsules are hardened at alkaline pH. Many such compounds, which may be simple or polymeric are mentioned including phenols, substituted (e.g. halogenated) phenols, phenolic carboxylic acids, biphenols and phenolic resins of the resor and novolak types. Suitable colloids in addition to gelatine are those of opposite charge, e.g. gum arabic, casein, alginate carrajunan, maleic acid/methyl vinyl ether copolymer and maleic acid/ethylene copolymer. A wide range of typical core materials (solid and liquid) are mentioned.
The symptoms of overdose with ropinirole are generally related to its dopaminergic activity. General supportive measures are recommended. Vital signs should be maintained, if necessary.

In the Parkinson's disease program, there have been patients who accidentally or intentionally took more than their prescribed dose of ropinirole. The largest overdose reported with ropinirole in clinical trials was 435 mg taken over a 7-day period (62.1 mg/day). Of patients who received a dose greater than 24 mg/day, reported symptoms included adverse events commonly reported during dopaminergic therapy (nausea, dizziness), as well as visual hallucinations, hyperhidrosis, claustrophobia, chorea, palpitations, asthenia, and nightmares. Additional symptoms reported for doses of 24 mg or less or for overdoses of unknown amount included vomiting, increased coughing, fatigue, syncope, vasovagal syncope, dyskinesia, agitation, chest pain, orthostatic hypotension, somnolence and confusional state.
The invention discloses a kind of treat rash after cloudy Chinese medicine of hindering type rotten larynx exanthema subitum, it is characterized in that being made up of the raw material of following weight proportion: Dendrobium densiflorum lindl. 10-12 part, Herba Cynanchi Thesioidis 20-25 part, Herba Dendrobii 15-18 part, Radix Puerariae Omeiensis 25-30 part, Rhizoma Polygonati Odorati 12-15 part, excellent careless 6-12 part, Radix Liriopes 12-15 part, Rhizoma Polygonati Verticillati 6-9 part, Zhejiang Radix Rehmanniae 25-30 part, Fructus Canarii albi root 20-30 part, Camellia sinensis O. Ktze. Var. macrophylla Sieb. 5-10 part, Arisaema balansae Engl. grass 20-30 part, the colored 10-15 part of firecracker, Herba Agerati Conyzoidis 20-25 part, Flos lupuli (Flos Humuli Lupuli) 6-9 part, Fructus artocarpi lingnanensis 15-20 part.Chinese medicine of the present invention, therapeutic effect is good, and curative effect is high, no longer recurs more.
The invention relates to biotechnology, to a method for producing a live influenza vaccine. The inventive method consists in cultivating passage cells in a nutritional medium, producing a virus-containing substance by cultivating vaccine strain of the influenza virus in the MDCK cell culture on the same nutritional medium. The vaccine cold-adapted reassortants of the influenza virus strains are used as virus strains. The nutritional medium for cultivating the MDCK cells and the influenza virus strains on said cells is embodied in the form of a serum-free nutritional medium supplemented with a soy hydrolysate at a concentration of 0.01-10.0 % and a proteolytic vegetable ferment in a quantity of 0.25-50.0 mkg/ml before inoculating seed dose of the influenza virus strains. The cultivation of MDCK culture cells and the vaccine influenza virus strains in said cell culture is carried out in a suspension based on microcarriers which are inoculated into the serum-free nutritional medium at a concentration of 1-6 g/l. Afterwards, ballast impurities are removed from a viral suspension, which is supplemented with a stabiliser and dried.
The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of naproxen may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [see Drug Interactions (7)].

Avoid the use of NAPROSYN Tablets, EC-NAPROSYN, or ANAPROX DS in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If NAPROSYN Tablets, EC-NAPROSYN, or ANAPROX DS is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

Since each ANAPROX DS tablet contains 50 mg of sodium (about 2 mEq per each 500 mg of naproxen), this should be considered in patients whose overall intake of sodium must be severely restricted.
Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.